![\"Sanofi](\"https:\/\/www.europesays.com\/france\/wp-content\/uploads\/2026\/05\/c45c40f5ed741dd9c0f5c2f75b8fc137.jpeg\")
Sanofi Winthrop Industrie <\/p>\n Sanofi Winthrop Industrie <\/p>\n
Sanofi\u2019s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses<\/p>\n
Paris, April 24, 2026. The European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Cenrifki (tolebrutinib) in the EU for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the last two years. A final decision is expected in the coming months.<\/p>\n
SPMS is a debilitating stage of multiple sclerosis where patients experience continuous accumulation of disability, including fatigue, cognitive impairment, mobility difficulties, and loss of independence \u2013 often without available treatment options. Addressing disability progression remains one of the most significant unmet needs in MS care.<\/p>\n
The positive CHMP opinion is based on data from the HERCULES phase 3 study (clinical study identifier: NCT04411641<\/a>) in non-relapsing SPMS, with supporting data from the GEMINI 1 (clinical study identifier: NCT04410978<\/a>) and GEMINI 2 (clinical study identifier: NCT04410991<\/a>) phase 3 studies in relapsing multiple sclerosis (RMS), which were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Conference 2024<\/a>, the American Academy of Neurology (AAN) 2025 Annual Meeting, and published in The New England Journal of Medicine<\/a>. The safety profile of Cenrifki has been consistent across the clinical program. Most common adverse events were COVID-19 and upper respiratory tract infections. Significant liver enzyme elevations were also observed. Drug-induced liver injury (DILI) is an identified safety risk of tolebrutinib. Strict adherence to liver monitoring requirements, and prompt management of liver enzyme elevations, are important to mitigate DILI risk.<\/p>\n Additional submissions for Cenrifki are currently under review with regulatory authorities worldwide.<\/p>\n About Cenrifki Cenrifki represents Sanofi’s commitment to developing innovative treatments that address the underlying causes of neurological diseases and potentially transform the treatment landscape. Standing at the intersection of neurology and immunoscience, Sanofi is focused on improving the lives of those living with serious neuroinflammatory and neurodegenerative conditions including MS, chronic inflammatory demyelinating polyneuropathy, Alzheimer\u2019s disease, Parkinson\u2019s disease, age-related macular degeneration, and other neurological diseases. The neurology pipeline currently has several projects in phase 3 studies across various diseases.<\/p>\n About Sanofi Media Relations Investor Relations Sanofi Forward-Looking Statements All trademarks mentioned in this press release are the property of the Sanofi group.<\/p>\n Attachment<\/p>\n","protected":false},"excerpt":{"rendered":"Sanofi Winthrop Industrie Sanofi\u2019s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple…\n","protected":false},"author":2,"featured_media":18814,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[14291,14293,14292,14288,14290,14294,14289,13012,14295],"class_list":["post-18870","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-american-academy-of-neurology","tag-clinical-study","tag-cognitive-impairment","tag-european-medicines-agency","tag-liver-enzyme-elevations","tag-phase-3-studies","tag-progressive-multiple-sclerosis","tag-sanofi","tag-tolebrutinib"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/18870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=18870"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/18870\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/18814"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=18870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=18870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=18870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Cenrifki (tolebrutinib) is an oral, brain-penetrant Bruton\u2019s tyrosine kinase inhibitor specifically designed to target smoldering neuroinflammation, a key driver of disability progression in MS. This mechanism addresses the underlying pathology of secondary progressive MS by targeting the inflammatory processes that contribute to disability accumulation.<\/p>\n
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people\u2019s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people\u2019s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY<\/p>\n
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com<\/a>
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com<\/a>\u00a0\u00a0
L\u00e9o Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com<\/a>\u00a0\u00a0
Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com<\/a>
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com<\/a>
L\u00e9a Ubaldi\u00a0| +33 6 30 19 66 46 |\u00a0lea.ubaldi@sanofi.com<\/a>
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pescheva@sanofi.com<\/p>\n
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com<\/a>
Aliz\u00e9 Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com<\/a>
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com<\/a>
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com<\/a>
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com<\/a>
Thibaud Ch\u00e2telet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com<\/a>
Yun Li\u00a0| +33 6 84 00 90 72 |\u00a0yun.li3@sanofi.com<\/a><\/p>\n
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201ccan,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cis designed to,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpotential,\u201d \u201cobjective,\u201d “attempt,” \u201ctarget,\u201d \u201cproject,\u201d “strategy,” “strive,” “desire,” \u201cpredict,\u201d \u201cforecast,\u201d \u201cambition,\u201d \u201cguideline,\u201d “seek,” \u201cshould,\u201d \u201cwill,\u201d “goal,” or the negative of these, and similar expressions are intended to identify forward-looking statements. Although Sanofi\u2019s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities\u2019 decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including \u201cmost favored nation\u201d pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi\u2019s ability to benefit from external growth opportunities, to complete related transactions and\/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation;\u00a0 trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under \u201cRisk Factors\u201d and \u201cCautionary Statement Regarding Forward-Looking Statements\u201d in Sanofi\u2019s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.<\/p>\n